PATENT CLAIM ANALYSIS

Application Number: 15986992
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-09
Patent Classification: ["424", "009100"]

Abstract:
S1P receptor modulators are administered following a dosage regimen providing a positive benefit-risk profile.

Claim (Index 21):
A method for treating multiple sclerosis in a patient in need thereof to limit risk of adverse effects of fingolimod, comprising\n (A) testing the patient for exposure to varicella zoster virus, and (i) if the patient tests negative, then vaccinate the patient against varicella zoster virus and proceed to step (B), or (ii) if the patient tests positive, proceed to step (B), (B) administering orally to the patient a daily dosage of 0.5 mg of fingolimod or a pharmaceutically acceptable salt thereof, (C) assessing the patient for a period of time, wherein the assessing comprises testing for infection in the patient, and (D) if the patient exhibits infection, then interrupting the administration, thereby limiting the risk of adverse effects.

Metadata:
- Claim Count in Document: 101.0
- Percentile: 93.0
- Lexical Diversity: 1.07143
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['12655049', '14973105', '15418572', '13985342', '13149468']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6712521014706299
- 35 USC 102 Novelty (BERT): 0.5024963731103764
- Combined Prediction Score: 0.6543765286346045
- Mean Citation Score: 219.731472
- Max Citation Score: 239.65294
- Similarity Product: 175.42600761785746

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test